Alastair Wilkins

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

C. Gieger, C. Freeman, P. Deloukas, 2013, Nature Genetics.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

J. Lechner-Scott, O. Pearson, M. Slee, 2017, The Lancet Neurology.

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

K. Selmaj, A. Coles, D. Margolin, 2010, Brain : a journal of neurology.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

M. Pirinen, P. Donnelly, C. Spencer, 2013, Nature Genetics.